Tag: talazoparib enzalutamide approval

Home / talazoparib enzalutamide approval

Categories

Talazoparib with enzalutamide is approved by FDA for HRR gene-mutated metastatic castration-resistant prostate cancer

July 2023: The Food and Drug Administration cleared talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene mutations in metastatic castration-resistant p...
talazoparib-enzalutamide-approval

Scan the code